

Further to the FTSE notice released on **02 August 2022** in relation to the takeover offer for Vifor Pharma AG. FTSE Russell confirms that due to Vifor Pharma AG suspending prior to market close with no closing auction, a synthetic price of USD 179.25 converted to CHF at the 4 August 4PM Spot rate will be used for the removal of Vifor Pharma AG.

Vifor Pharma AG - Tendered Line (Switzerland): Constituent Deletion - Removal Price Confirmation Changes in FTSE RAFI™ Index Series

04 August 2022

Following the remaining regulatory approval of the takeover offer for Vifor Pharma AG - Tendered Line (Switzerland, constituent) by CSL Behring AG (non constituent), and with acceptances reaching in excess of 90%, please see details of affected indexes and effective dates below:

Index	Effective From Start of Trading
FTSE RAFI Developed ex US 1000	05 August 2022
FTSE RAFI Developed ex US 1000 Index - QSR	05 August 2022
FTSE RAFI All World 3000 Index	05 August 2022
FTSE RAFI All World 3000 Index - QSR	05 August 2022

Please note: Vifor Pharma AG - Tendered Line will be removed using the CHF equivalent of the offer terms of USD 179.25.

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia	+1800 653 680
Hong Kong	+852 2164 3333
Japan	+81 3 6441 1440
London	+44 (0) 20 7866 1810
New York	+1866 551 0617

Alternatively please visit our website at www.ftserussell.com

Terms of Use | Copyright © 2022 FTSE Russell